Literature DB >> 33129248

Clinical implications of the glucokinase impaired function - GCK MODY today.

J Hulín1, M Škopková, T Valkovičová, S Mikulajová, M Rosoľanková, P Papcun, D Gašperíková, J Staník.   

Abstract

Heterozygous inactivating mutations of the glucokinase (GCK) gene are causing GCK-MODY, one of the most common forms of the Maturity Onset Diabetes of the Young (MODY). GCK-MODY is characterized by fasting hyperglycemia without apparent worsening with aging and low risk for chronic vascular complications. Despite the mild clinical course, GCK-MODY could be misdiagnosed as type 1 or type 2 diabetes. In the diagnostic process, the clinical suspicion is often based on the clinical diagnostic criteria for GCK-MODY and should be confirmed by DNA analysis. However, there are several issues in the clinical and also in genetic part that could complicate the diagnostic process. Most of the people with GCK-MODY do not require any pharmacotherapy. The exception are pregnant women with a fetus which did not inherit GCK mutation from the mother. Such a child has accelerated growth, and has increased risk for diabetic foetopathy. In this situation the mother should be treated with substitutional doses of insulin. Therefore, distinguishing GCK-MODY from gestational diabetes in pregnancy is very important. For this purpose, special clinical diagnostic criteria for clinical identification of GCK-MODY in pregnancy are used. This review updates information on GCK-MODY and discusses several currently not solved problems in the clinical diagnostic process, genetics, and treatment of this type of monogenic diabetes.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33129248      PMCID: PMC8549873          DOI: 10.33549/physiolres.934487

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  92 in total

1.  Identification of 14 new glucokinase mutations and description of the clinical profile of 42 MODY-2 families.

Authors:  G Velho; H Blanché; M Vaxillaire; C Bellanné-Chantelot; V C Pardini; J Timsit; P Passa; I Deschamps; J J Robert; I T Weber; D Marotta; S J Pilkis; G M Lipkind; G I Bell; P Froguel
Journal:  Diabetologia       Date:  1997-02       Impact factor: 10.122

2.  ISPAD Clinical Practice Consensus Guidelines 2014. The diagnosis and management of monogenic diabetes in children and adolescents.

Authors:  Oscar Rubio-Cabezas; Andrew T Hattersley; Pål R Njølstad; Wojciech Mlynarski; Sian Ellard; Neil White; Dung Vu Chi; Maria E Craig
Journal:  Pediatr Diabetes       Date:  2014-09       Impact factor: 4.866

3.  Aetiological heterogeneity of asymptomatic hyperglycaemia in children and adolescents.

Authors:  E Feigerlová; S Pruhová; L Dittertová; J Lebl; D Pinterová; K Kolostová; M Cerná; O Pedersen; T Hansen
Journal:  Eur J Pediatr       Date:  2006-04-07       Impact factor: 3.183

4.  Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations.

Authors:  Anna L Gloyn; Kees Noordam; Michèl A A P Willemsen; Sian Ellard; Wayne W K Lam; Ian W Campbell; Paula Midgley; Chyio Shiota; Carol Buettger; Mark A Magnuson; Franz M Matschinsky; Andrew T Hattersley
Journal:  Diabetes       Date:  2003-09       Impact factor: 9.461

5.  Pancreatic beta-cell-specific targeted disruption of glucokinase gene. Diabetes mellitus due to defective insulin secretion to glucose.

Authors:  Y Terauchi; H Sakura; K Yasuda; K Iwamoto; N Takahashi; K Ito; H Kasai; H Suzuki; O Ueda; N Kamada
Journal:  J Biol Chem       Date:  1995-12-22       Impact factor: 5.157

6.  Diagnostic screening of MODY2/GCK mutations in the Norwegian MODY Registry.

Authors:  Jørn V Sagen; Lise Bjørkhaug; Janne Molnes; Helge Raeder; Louise Grevle; Oddmund Søvik; Anders Molven; Pål R Njølstad
Journal:  Pediatr Diabetes       Date:  2008-04-09       Impact factor: 4.866

7.  High prevalence of glucokinase mutations in Italian children with MODY. Influence on glucose tolerance, first-phase insulin response, insulin sensitivity and BMI.

Authors:  O Massa; F Meschi; A Cuesta-Munoz; A Caumo; F Cerutti; S Toni; V Cherubini; L Guazzarotti; N Sulli; F M Matschinsky; R Lorini; D Iafusco; F Barbetti
Journal:  Diabetologia       Date:  2001-07       Impact factor: 10.122

8.  The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes.

Authors:  B M Shields; T J McDonald; S Ellard; M J Campbell; C Hyde; A T Hattersley
Journal:  Diabetologia       Date:  2012-01-05       Impact factor: 10.122

9.  Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia.

Authors:  Anna M Steele; Beverley M Shields; Kirsty J Wensley; Kevin Colclough; Sian Ellard; Andrew T Hattersley
Journal:  JAMA       Date:  2014-01-15       Impact factor: 56.272

10.  Hypothalamic arcuate nucleus glucokinase regulates insulin secretion and glucose homeostasis.

Authors:  Yue Ma; Risheka Ratnasabapathy; Chioma Izzi-Engbeaya; Marie-Sophie Nguyen-Tu; Errol Richardson; Sufyan Hussain; Ivan De Backer; Christopher Holton; Mariana Norton; Gaelle Carrat; Blanche Schwappach; Guy A Rutter; Waljit S Dhillo; James Gardiner
Journal:  Diabetes Obes Metab       Date:  2018-06-12       Impact factor: 6.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.